Ironwood Pharma (IRWD) Misses Q3 EPS by 4c; Offers Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q3 EPS of $0.28, $0.04 worse than the analyst estimate of $0.32. Revenue for the quarter came in at $108.64 million versus the consensus estimate of $110.15 million.

GUIDANCE:

Ironwood Pharma sees FY2022 revenue of $420-430 million, versus the consensus of $422.7 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• Apogee Enterprises (APOG) Tops Q1 EPS by 16c, Beats on Revenue; Offers FY27 Guidance
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Trip.com Group (TCOM) Misses Q1 EPS by 41c